|
1
|
Peng X, Holler CJ, Alves AMF, Oliviera MG, Speake M, Pugliese A, Oskouei MR, de Freitas ID, Chen AYP, Gallegos R, McTighe SM, Koenig G, Hurst RS, Blain JF, Lanter JC, Burnett DA. Discovery and characterization of novel TRPML1 agonists. Bioorg Med Chem Lett 2024; 98:129595. [PMID: 38141860 DOI: 10.1016/j.bmcl.2023.129595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 11/30/2023] [Accepted: 12/17/2023] [Indexed: 12/25/2023]
Abstract
Screening a library of >100,000 compounds identified the substituted tetrazole compound 1 as a selective TRPML1 agonist. Both enantiomers of compound 1 were separated and profiled in vitro and in vivo. Their selectivity, ready availability and CNS penetration should enable them to serve as the tool compounds of choice in future TRPML1 channel activation studies. SAR studies on conformationally locked macrocyclic analogs further improved the TRPML1 agonist potency while retaining the selectivity.
Collapse
Affiliation(s)
- Xiaowen Peng
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA.
| | | | - Anna-Maria F Alves
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Michelle G Oliviera
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Michael Speake
- BioAscent Discovery Ltd, Bo'Ness Rd, Chapelhall, Motherwell ML1 5UH, United Kingdom
| | - Angelo Pugliese
- BioAscent Discovery Ltd, Bo'Ness Rd, Chapelhall, Motherwell ML1 5UH, United Kingdom
| | - Mina R Oskouei
- Symeres Inc, Kerkenbos 1013, 6546 BB Nijmegen, the Netherlands
| | | | - Angela Y-P Chen
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Richard Gallegos
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Stephanie M McTighe
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Gerhard Koenig
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Raymond S Hurst
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Jean-François Blain
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - James C Lanter
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| | - Duane A Burnett
- Arkuda Therapeutics, 200 Arsenal Yards Blvd Suite 220, Watertown, MA 02472, USA
| |
Collapse
|
|
2
|
Schmidt D. Introduction to special issue on rare disease drug discovery. Bioorg Med Chem 2023; 92:117375. [PMID: 37474404 DOI: 10.1016/j.bmc.2023.117375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/22/2023]
Affiliation(s)
- Darby Schmidt
- CSO, Violet Therapeutics, 101 Main St., Suite 510, Cambridge, MA 02142, USA
| |
Collapse
|